The European Commission approved, on Monday 25 July, the extension of the use of the smallpox vaccine Imvanex developed by Bavarian Nordic A/S for the treatment of monkeypox (see EUROPE B12998A24). This vaccine is subject to a European joint purchase agreement(see EUROPE B12995A35).
The response to this outbreak was the topic of a video conference by the European Commission’s Directorate-General for Health, represented by Commissioner Stella Kyriakides, the European Medicines Agency...